Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
28
ELDN Quote, Financials, Valuation and Earnings
Last price:
$1.58
Seasonality move
:
-1.34%
Day range:
$1.52 - $1.61
52-week range:
$1.35 - $4.98
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.33x
Volume:
353.5K
Avg. volume:
1.8M
1-year change:
-63.23%
Market cap:
$117.8M
Revenue:
--
EPS (TTM):
-$1.20
Analysts' Opinion
-
Consensus RatingEledon Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $8.00, Eledon Pharmaceuticals, Inc. has an estimated upside of 409.55% from its current price of $1.57.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.00 representing 100% downside risk from its current price of $1.57.
Fair Value
-
According to the consensus of 7 analysts, Eledon Pharmaceuticals, Inc. has 409.55% upside to fair value with a price target of $8.00 per share.
ELDN vs. S&P 500
-
Over the past 5 trading days, Eledon Pharmaceuticals, Inc. has underperformed the S&P 500 by -1.41% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Eledon Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Eledon Pharmaceuticals, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Eledon Pharmaceuticals, Inc. reported revenues of --.
Earnings Growth
-
Eledon Pharmaceuticals, Inc. has grown year-over-year earnings for 6 quarters straight. In the most recent quarter Eledon Pharmaceuticals, Inc. reported earnings per share of -$0.23.
Enterprise value:
80.8M
EV / Invested capital:
0.88x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.20x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$88K
Return On Assets:
-51.14%
Net Income Margin (TTM):
--
Return On Equity:
-78.86%
Return On Invested Capital:
-78.27%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$373K | -$365K | -$88K | -$79K | -- | |
| Operating Income | -$42.7M | -$56.2M | -$86.5M | -$20.5M | -$19.1M | |
| EBITDA | -$42.3M | -$55.9M | -$86.4M | -$20.4M | -$19.1M | |
| Diluted EPS | -$8.06 | -$5.71 | -$1.20 | -$0.32 | -$0.23 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $95.6M | $67.6M | $63M | $81.5M | $96.3M | |
| Total Assets | $177.2M | $149.6M | $96.1M | $114.6M | $129.9M | |
| Current Liabilities | $4M | $6.3M | $2.9M | $12.5M | $14.3M | |
| Total Liabilities | $6.4M | $8.5M | $4.7M | $38.5M | $38.8M | |
| Total Equity | $170.7M | $141.1M | $91.3M | $76.1M | $91.1M | |
| Total Debt | $222K | $461K | $83K | $315K | $376K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$39.9M | -$37.4M | -$67.2M | -$11.8M | -$14.5M | |
| Cash From Investing | -$55.4M | -$12.9M | -$16.1M | -$12.8M | $12.4M | |
| Cash From Financing | $33M | $53.4M | $80.3M | $5.3M | -- | |
| Free Cash Flow | -$39.9M | -$37.4M | -$67.2M | -$11.8M | -$14.5M | |
ELDN
Sector
Market Cap
$117.8M
$28M
Price % of 52-Week High
31.53%
51.03%
Dividend Yield
0%
0%
Shareholder Yield
-51.77%
-1.54%
1-Year Price Total Return
-63.23%
-17.48%
Beta (5-Year)
0.793
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.61
200-day SMA
Sell
Level
$2.85
Bollinger Bands (100)
Sell
Level
1.76 - 3.28
Chaikin Money Flow
Buy
Level
17.6M
20-day SMA
Sell
Level
$1.60
Relative Strength Index (RSI14)
Sell
Level
39.31
ADX Line
Sell
Level
30.26
Williams %R
Neutral
Level
-75.5102
50-day SMA
Sell
Level
$2.39
MACD (12, 26)
Sell
Level
-0.14
25-day Aroon Oscillator
Buy
Level
48
On Balance Volume
Sell
Level
-19.4M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-1.1657)
Sell
CA Score
(Annual)
Level (-2.9327)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (7)
Sell
Ohlson Score
Level (2.576)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (2)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The firm’s compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential. The CD40L/CD40 pathway is recognized for its prominent role in immune regulation, making it a candidate for therapeutic intervention in transplant tolerance, autoimmune disease, and neuro-inflammation. The company is building upon a deep historical understanding of the CD40/CD40L pathway, as well as preclinical and Phase 1 data, to initiate up to four phase 2 clinical studies with AT-1501. The company was founded on March 26, 2004 and is headquartered in Irvine, CA.
Stock Forecast FAQ
In the current month, ELDN has received 7 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ELDN average analyst price target in the past 3 months is $8.00.
-
Where Will Eledon Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Eledon Pharmaceuticals, Inc. share price will rise to $8.00 per share over the next 12 months.
-
What Do Analysts Say About Eledon Pharmaceuticals, Inc.?
Analysts are divided on their view about Eledon Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Eledon Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $4.00.
-
What Is Eledon Pharmaceuticals, Inc.'s Price Target?
The price target for Eledon Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $8.00 according to 7 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ELDN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Eledon Pharmaceuticals, Inc. is a Buy. 7 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ELDN?
You can purchase shares of Eledon Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Eledon Pharmaceuticals, Inc. shares.
-
What Is The Eledon Pharmaceuticals, Inc. Share Price Today?
Eledon Pharmaceuticals, Inc. was last trading at $1.58 per share. This represents the most recent stock quote for Eledon Pharmaceuticals, Inc.. Yesterday, Eledon Pharmaceuticals, Inc. closed at $1.57 per share.
-
How To Buy Eledon Pharmaceuticals, Inc. Stock Online?
In order to purchase Eledon Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ELDN Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ELDN
Sector
P/E ratio
--
23.89x
PEG ratio
--
-0.01x
P/B ratio
3.33x
1.82x
Price / LTM sales
--
1.60x
Growth Metrics
ELDN
Sector
Revenue growth
--
4.62%
Earnings growth
28.27%
10.88%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$0.25
-$0.21
Profitability
ELDN
Sector
Profitability FY 2024
-$359K
$3.5M
Return on invested capital
-78.27%
-31.77%
Return on assets
-51.14%
-27.96%
Return on equity
-78.86%
-37.63%
Earnings Date
Last Earnings Date
Nov
14
Next Earnings Date
Mar
19
Estimated Next Earnings Date
Feb
13
Balance Sheet
ELDN
Sector
Total cash
$93.4M
$26.3M
Short term investments
$119.6M
$25.7M
Total assets
$229.4M
$78M
Long term debt
$376K
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
